These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24343157)

  • 1. Multiple sclerosis disease progression and paradichlorobenzene: a tale of mothballs and toilet cleaner.
    Hession RM; Sharma V; Spiegel DE; Tat C; Hwang DG; Dieppa M; Mahdavi Z; Marder E; Stüve O
    JAMA Neurol; 2014 Feb; 71(2):228-32. PubMed ID: 24343157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradichlorobenzene (toxin)-induced leucoencephalopathy.
    Buckman F
    BMJ Case Rep; 2013 Apr; 2013():. PubMed ID: 23608871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pica with paradichlorobenzene mothball ingestion associated with toxic leukoencephalopathy.
    Avila E; Schraeder P; Belliappa A; Faro S
    J Neuroimaging; 2006 Jan; 16(1):78-81. PubMed ID: 16483281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mothball induced encephalopathy presenting as depression: it's all in the history.
    Murray SB; Dwight-Johnson M; Levy MR
    Gen Hosp Psychiatry; 2010; 32(3):341.e7-9. PubMed ID: 20430245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemolytic anemia induced by ingestion of paradichlorobenzene mothballs.
    Sillery JJ; Lichenstein R; Barrueto F; Teshome G
    Pediatr Emerg Care; 2009 Apr; 25(4):252-4. PubMed ID: 19369838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Toilet cake" encephalopathy.
    Zhang Z; Moreno A
    J Addict Med; 2014; 8(6):474-5. PubMed ID: 25187976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Case of opticospinal multiple sclerosis showing phenotype change to conventional type induced by interferon beta-1b].
    Kanzaki M; Yomono H; Ogawa G; Motoyoshi K; Kurisaki H; Kamakura K
    Rinsho Shinkeigaku; 2007; 47(2-3):100-4. PubMed ID: 17511277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of naphthalene and paradichlorobenzene mothballs based on their difference in specific gravity.
    Fukuda T; Koyama K; Yamashita M; Koichi N; Takeda M
    Vet Hum Toxicol; 1991 Aug; 33(4):313-4. PubMed ID: 1897123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mothball differentiation: naphthalene from paradichlorobenzene.
    Winkler JV; Kulig K; Rumack BH
    Ann Emerg Med; 1985 Jan; 14(1):30-2. PubMed ID: 3965000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features of relapsing remitting-multiple sclerosis. Prognostic factors].
    Fernández-Fernández O
    Rev Neurol; 2002 Dec 1-15; 35(11):1067-73. PubMed ID: 12497314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
    Baumgartner A; Stich O; Rauer S
    Int J Neurosci; 2012 Jan; 122(1):35-9. PubMed ID: 21913869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
    Berger JR
    Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical disk pathology in patients with multiple sclerosis: two case reports.
    Mullen AE; Wilmarth MA; Lowe S
    Phys Ther; 2012 Aug; 92(8):1055-64. PubMed ID: 22517783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Radue EW; Lublin FD; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):911-23. PubMed ID: 16510745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis.
    Papadopoulos K; Tozer DJ; Fisniku L; Altmann DR; Davies G; Rashid W; Thompson AJ; Miller DH; Chard DT
    Mult Scler; 2010 Apr; 16(4):427-33. PubMed ID: 20086026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.